NASDAQ$YMAB
Y-mAbs Therapeutics Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Y-mAbs' first quarter results for 2024 were reported, featuring U.S. DANYELZA® net product revenues of $18.6 million, and worldwide DANYELZA net product revenues of $19.4 million.
Y-mAbs reported its Q1 2024 financial results, highlighting the highest quarter of U.S. demand for DANYELZA® since its launch and progress in clinical development initiatives, particularly the SADA PRIT Technology platform. The company's financial guidance for the full year 2024 was reiterated, expecting to continue operations into 2027.
- U.S. DANYELZA® net product revenues reached $18.6 million, an 11% increase year-over-year.
- Worldwide DANYELZA net product revenues were $19.4 million, a 4% decrease year-over-year.
- Cash and cash equivalents totaled $75.7 million as of March 31, 2024, with a cash burn of $2.9 million for the quarter.
- Full year 2024 financial guidance and anticipated cash runway into 2027 were reiterated.
Headline financials
Revenue & EPS history
Y-mAbs · Revenue · Quarterly
$19.9M
Forward guidance
Management reiterated its full year 2024 financial guidance.
Tailwinds
- Anticipated total DANYELZA® net product revenues of between $95 million and $100 million.
- Anticipated operating expenses of between $115 million and $120 million.
- Anticipated total annual cash burn of between $15 million and $20 million.
- Cash and cash equivalents anticipated to continue to support operations as currently planned into 2027.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 5 quarterly earnings reports · overlaid with Q1 2024
+2.2%
Avg return
Earnings day
-4.2%
Avg return
5 days after
-5.4%
Avg return
30 days after
36%
10 / 28 earnings
Positive
+54.6%
Q4 2022
Best reaction
-21.1%
Q1 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q3 2025 | — | — | — | |
| Q2 2025 | +0.0% | +0.0% | +0.8% | |
| Q1 2025 | -11.4% | +0.2% | +14.0% | |
| Q4 2024 | -4.4% | -0.4% | -9.9% | |
| Q3 2024 | -4.4% | -15.2% | -32.3% | |
| Q2 2024 | -3.5% | +9.4% | +18.4% | |
| Q1 2024 | -21.1% | -25.4% | -28.7% | |
| Q4 2023 | +14.5% | +2.0% | -0.2% | |
| Q3 2023 | +6.1% | — | — | |
| Q2 2023 | -5.0% | — | — | |
| Q1 2023 | +33.6% | — | — | |
| Q4 2022 | +54.6% | — | — | |
| Q3 2022 | +15.4% | — | — | |
| Q2 2022 | -5.6% | — | — | |
| Q1 2022 | +13.2% | — | — | |
| Q4 2021 | +12.9% | — | — | |
| Q3 2021 | -19.7% | — | — | |
| Q2 2021 | -17.8% | — | — | |
| Q1 2021 | +20.8% | — | — | |
| Q4 2020 | -3.6% | — | — | |
| Q3 2020 | -3.0% | — | — | |
| Q2 2020 | -1.6% | — | — | |
| Q1 2020 | +14.4% | — | — | |
| Q4 2019 | -8.7% | — | — | |
| Q3 2019 | -1.6% | — | — | |
| Q2 2019 | +2.4% | — | — | |
| Q1 2019 | -9.9% | — | — | |
| Q4 2018 | -4.4% | — | — | |
| Q3 2018 | -1.1% | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro